The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
Increasing Alzheimer’s Patients Spell Drug Profits
Some disturbing figures rolled out yesterday concerning growth rates of Alzheimer’s patients. The number of people affected grew 10% in the past four years and is expected to grow to over 115 million by 2050. That’s a doubling of cases every 20 years.
The number is expected to grow because of the diets and activity levels amongst older individuals in developed countries. Apparently we’re getting too much junk food and not enough exercise.
Numbers like that are scary to contemplate for many, especially families with relatives at risk, but they’re statistics that pharmaceutical companies love hearing.
Which is why we thought we’d pull up a few of the leading Alheimer’s drugs and the publicly listed companies that produce them: drugs like Aricept from Pfizer (NYSE: PFE), Exelon from Novartis AG ADR (NYSE: NVS), and Namenda from Forest Laboratories (NYSE: FRX).
With ever increasing Alzheimer’s customers to buy these products, these companies should have their hands full, and that bodes well for investors.
And in another strange coincidence, researchers at the University of Alabama have just discovered a link between individuals who have difficulty with their finances and dementia. We can see no better reason to continue reading Investment U and keeping educated about you finances.
Symbols mentioned in this article: PFE, NVS and FRX.
- Alzheimer’s Care Key to Healthcare Facilities Sector
- Becton Dickson and Company (NYSE: BDX): Stock of the Day
- Pozen Inc. (Nasdaq: POZN): Stock of the Day
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed